<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637973</url>
  </required_header>
  <id_info>
    <org_study_id>EmLiFa001</org_study_id>
    <nct_id>NCT02637973</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes</brief_title>
  <acronym>EmLiFa</acronym>
  <official_title>Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Deutsche Diabetes Forschungsgesellschaft e.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of empagliflozin treatment on hepatocellular lipid content, liver energy&#xD;
      metabolism and body composition will be investigated in a multicentre, prospective,&#xD;
      placebo-controlled, double-blind, randomized, 2-arm parallel, interventional and exploratory&#xD;
      pilot study in patients with newly diagnosed type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multicentre, prospective, placebo-controlled, double-blind, randomized, 2-arm&#xD;
      parallel, interventional pilot study HCL and intramyocellular lipids (IMCL) will be&#xD;
      quantified with 1H magnetic resonance (MR) spectroscopy. Hepatic ATP and inorganic phosphate&#xD;
      (Pi) concentrations will be assessed with 31P MR spectroscopy (1). Whole-body and hepatic&#xD;
      insulin sensitivity and metabolic flexibility will be measured by combining&#xD;
      hyperinsulinemic-euglycemic pancreatic clamp tests with isotopic dilution of 6,6-2H2 glucose&#xD;
      and indirect calorimetry as shown (2). Abdominal fat distribution will be quantified by MR&#xD;
      imaging.&#xD;
&#xD;
      Newly diagnosed patients with type 2 diabetes (T2D) will be randomly allocated to once daily&#xD;
      25 mg empagliflozin (EMPA) or placebo for 24 weeks with a computer-generated random sequence&#xD;
      and will be masked to the treatment assignment. Participants will visit the clinical research&#xD;
      center at baseline, 12 weeks and 24 weeks for MRS and metabolic examinations, including blood&#xD;
      sampling for hepato- and adipocytokines. Anthropometric parameters (body weight, waist&#xD;
      circumference, total body fat, blood pressure) and glycemic control (HbA1C, fasting blood&#xD;
      glucose, FBG) will be assessed at baseline and during monitoring visits every 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver fat content</measure>
    <time_frame>from baseline to 24 weeks</time_frame>
    <description>Change in liver fat content between baseline and 24 weeks measured with magnetic resonance spectroscopy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin, film-tablet, 25mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>25 mg once daily</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 75 years&#xD;
&#xD;
          -  BMI&lt;45 kg/m2&#xD;
&#xD;
          -  known diabetes duration up to 7 years&#xD;
&#xD;
          -  6%≤HbA1c≤8%&#xD;
&#xD;
          -  drug naïve - no previous antihyperglycemic treatment or one month washout period of&#xD;
             treatment with oral glucose lowering drugs (no previous treatment with&#xD;
             thiazolidinedione (TZD) drugs allowed)&#xD;
&#xD;
          -  obtained written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled hyperglycaemia at screening (glucose level ≥240 mg/dl after an overnight&#xD;
             fast, confirmed by a second measurement)&#xD;
&#xD;
          -  acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to&#xD;
             consent&#xD;
&#xD;
          -  previous lower limb amputation&#xD;
&#xD;
          -  severe lower limb infection/ulceration within 3 months prior to consent&#xD;
&#xD;
          -  liver disease including chronic viral hepatitis (B or C), alcohol abuse,&#xD;
             hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's&#xD;
             disease, primary sclerosing cholangitis or primary biliary cirrhosis, or liver&#xD;
             cirrhosis of any etiology&#xD;
&#xD;
          -  AST or ALT &gt; 3 x ULN&#xD;
&#xD;
          -  positive result on hepatitis B (HBs-AG), hepatitis C (HCV-AB), or HIV 1 and 2 test&#xD;
&#xD;
          -  impaired kidney function (estimated glomerular filtration rate [eGFR]&lt;60&#xD;
             mL/min/1.73m2) during screening&#xD;
&#xD;
          -  structural and functional urogenital abnormalities, that predispose for urogenital&#xD;
             infections&#xD;
&#xD;
          -  gastrointestinal surgeries that induce chronic malabsorption&#xD;
&#xD;
          -  history of cancer (except basal cell carcinoma) or treatment for cancer within 5 years&#xD;
&#xD;
          -  blood dyscrasias or any disorders causing haemolysis or unstable erythrocytes&#xD;
&#xD;
          -  treatment with antiobesity drugs 3 months prior to consent&#xD;
&#xD;
          -  treatment with immunomodulatory drugs (oral steroids, antihistamines)&#xD;
&#xD;
          -  change in dosage of thyroid hormones within 6 weeks of consent&#xD;
&#xD;
          -  pregnancy, lactation period&#xD;
&#xD;
          -  metal or magnetic implants, devices or objects inside of or on the body, which are not&#xD;
             MRI compatible (according to MRT safety checklist in Appendix 11.3)&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  cigarette smoking (non-smoker &lt; 1year), alcohol consumption (male &gt;30 g/d, female&#xD;
             &gt;20g/d)&#xD;
&#xD;
          -  drug abuse or psychiatric disease&#xD;
&#xD;
          -  night-worker or circumstances not allowing normal day-night rhythm&#xD;
&#xD;
          -  hypersensitivity to empagliflozin (or drugs of similar chemical structure) or any of&#xD;
             the drug compounds&#xD;
&#xD;
          -  pharmaceutical preparations with which interactions can be expected - amiloride,&#xD;
             furosemide, indapamide, spironolactone, torasemide, triamterene&#xD;
&#xD;
          -  use of anti-NASH drugs (vitamin E, ursodeoxycholic acid, S-adenosylmethionine,&#xD;
             betaine, silymarin, gemfibrozil, anti-TNF therapies, probiotics) in the 3 months prior&#xD;
             to randomization&#xD;
&#xD;
          -  women of childbearing potential not using two adequate methods of contraception&#xD;
             including a barrier method and a highly efficacious non-barrier method&#xD;
&#xD;
          -  persons with any kind of dependency on the investigator or employed by the sponsor or&#xD;
             investigator&#xD;
&#xD;
          -  persons held in an institution by legal or official order&#xD;
&#xD;
          -  participation in another trial in the last 10 weeks before randomization or planned&#xD;
             participation during the trial period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

